Claude Fable 5.1 for Business Automation: What Changed and What It Costs
On the benchmark that measures automating actual business processes, Claude Fable 5.1 scored 31.4% — up from 17.1% for Claude Fable 5, released three months earlier. Anthropic calls that benchmark AutomationBench. A near-doubling in one release cycle is the number worth stopping on, because most of the automation work I build for clients lives or dies on exactly that capability: can the model finish a multi-step job without a human stepping in. Here is a clear-eyed read of what Claude Fable 5.1 changes for business automation, what it actually costs once you account for how it behaves, and when Fable 5 or Opus 5 is still the right call. TL;DR Anthropic released Claude Fable 5.1 and Mythos 5.1 on 1 September 2026. Fable 5.1 is generally available; Mythos 5.1 is restricted to vetted cybersecurity and life-sciences organisations. Anthropic reports Fable 5.1 scores 31.4% on AutomationBench (business-workflow automation), up from 17.1% for Fable 5, with large gains on agentic coding and research benchmarks too. Base API pricing is unchanged at $10 / $50 per million input/output tokens. The one cut is cache reads, down 75% to $0.25 per million. Independent analysis by Stork.AI reports Fable 5.1 emits about 1.7x more output tokens per task, so it is cheaper only when cached context dominates your spend — long-running agents on a stable codebase or knowledge base. For varied one-off prompts, Opus 5 or Sonnet 5 is better economics. What is Claude Fable 5.1? Claude Fable 5.1 is Anthropic's flagship model for coding and knowledge work, released on 1 September 2026 as an incremental upgrade to Claude Fable 5. The same underlying model ships in two safeguard configurations: Fable 5.1 — generally available. API id claude-fable-5-1 , on the Anthropic API, Amazon Bedrock, Google Cloud Vertex AI, Microsoft Azure AI Foundry, Claude Code and Claude Enterprise. Mythos 5.1 — restricted. Lighter safeguards for vetted organisations via Anthropic's Cyber Verification and Life Sciences Veri